Detalhe da pesquisa
1.
Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).
Br J Haematol
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38654616
2.
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
Ann Hematol
; 2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38443660
3.
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Blood
; 137(8): 1019-1023, 2021 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33167024
4.
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica
; 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031755
5.
Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma.
Haematologica
; 107(9): 2163-2172, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35172560
6.
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Br J Haematol
; 194(2): 393-402, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34195988
7.
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
Ann Hematol
; 100(4): 987-993, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33495922
8.
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.
N Engl J Med
; 377(13): 1250-1260, 2017 09 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28953447
9.
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.
Blood
; 131(17): 1955-1959, 2018 04 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29437588
10.
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
Haematologica
; 104(1): 138-146, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30171024
11.
Characteristics, combinations, treatments, and survival of second primary hematological neoplasm: a retrospective single-center cohort of 49 patients (Hemo2study).
Ann Hematol
; 98(10): 2367-2377, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31455988
12.
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.
Haematologica
; 103(11): 1889-1898, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29976743
13.
Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization.
Am J Hematol
; 96(9): E311-E314, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34000073
14.
Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).
Br J Haematol
; 186(1): 146-149, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30548257
15.
Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17 years' experience in a single centre.
Ann Hematol
; 93(1): 147-156, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24232218
16.
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.
Am J Hematol
; 94(7): E183-E185, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30945328
17.
Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.
Am J Hematol
; 89(4): 410-6, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24375487
18.
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.
Blood
; 117(2): 403-11, 2011 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-20940414
19.
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.
Haematologica
; 103(8): e356-e359, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29519866
20.
Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).
Am J Hematol
; 93(2): E52-E54, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29164674